Effect of delay in treatment intensification in people with type 2 diabetes and suboptimal glycaemia after basal insulin initiation: A real-world observational study.
basal insulin
delay in intensification
micro- and macrovascular complications
suboptimal glycaemia
therapeutic inertia
type 2 diabetes mellitus
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
19 Oct 2023
19 Oct 2023
Historique:
revised:
25
09
2023
received:
16
08
2023
accepted:
03
10
2023
medline:
20
10
2023
pubmed:
20
10
2023
entrez:
19
10
2023
Statut:
aheadofprint
Résumé
Despite global recommendations for type 2 diabetes mellitus treatment to maintain optimal glycaemic targets, a significant proportion of people remain in suboptimal glycaemic control. Our objective was to investigate the impact of intensification delay after basal insulin (BI) initiation on long-term complications in people with suboptimal glycaemia. We conducted a retrospective cohort study in individuals with type 2 diabetes mellitus initiated on BI. Those with suboptimal glycaemia (glycated haemoglobin ≥7% or ≥53 mmol/mol) within 12 months of BI initiation were divided into early (treatment intensified within 5 years), or late (≥5 years) intensification groups. We estimated the age-stratified risks of micro- and macrovascular complications among these groups compared with those with optimal glycaemia (glycated haemoglobin <7%). Of the 13 916 people with suboptimal glycaemia, 52.5% (n = 7304) did not receive any treatment intensification. In those aged <65 years, compared with the optimal glycaemia group late intensification was associated with a 56% higher risk of macrovascular complications (adjusted hazard ratio 1.56; 95% confidence intervals 1.08, 2.26). In elderly people (≥65 years), late intensification was associated with a higher risk of cardiovascular-related death (1.62; 1.03, 2.54) and a lower risk of microvascular complications (0.26; 0.08, 0.83). Those who had late intensification were at an increased risk of cardiovascular death if they were ≥65 years and an increased risk of macrovascular complications if they were <65 years. These findings highlight the critical need for earlier intensification of treatment and adopting personalized treatment strategies to improve patient outcomes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Sanofi
Informations de copyright
© 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
American Diabetes Association. Economic costs of diabetes in the US in 2017. Diabetes Care. 2018;41(917):917-928.
Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2022 Nov;45(11):2753-2786. Available from: https://diabetesjournals.org/care/article/45/11/2753/147671/Management-of-Hyperglycemia-in-Type-2-Diabetes
Elsayed NA, Aleppo G, Aroda VR, et al. 6. Glycemic targets: standards of care in diabetes-2023. Diabetes Care. 2023;46:S97-S110. doi:10.2337/dc23-S006
Reaven PD, Emanuele NV, Wiitala WL, et al. Intensive glucose control in patients with type 2 diabetes - 15-year follow-up. N Engl J Med. 2019 Jun;380(23):2215-2224.
Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14(1):1-10.
Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27(7):1535-1540.
Coan KE, Schlinkert AB, Beck BR, Haakinson DJ, Castro JC, Apsey HA. Clinical inertia during postoperative management of diabetes mellitus: relationship between hyperglycemia and insulin therapy intensification. J Diabetes Sci Technol. 2013;7(4):880-887.
Yam FK, Adams AG, Divine H, Steinke D, Jones MD. Clinical inertia in type 2 diabetes: a retrospective analysis of pharmacist-managed diabetes care vs. usual medical care. Pharm Pract (Granada). 2013;11(4):203-210.
Khunti S, Khunti K, Seidu S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Ther Adv Endocrinol Metab. 2019;10:204201881984469.
Bin Rsheed A, Chenoweth I. Barriers that practitioners face when initiating insulin therapy in general practice settings and how they can be overcome. World J Diabetes. 2017;8(1):28-39.
Perreault L, Vincent L, Neumiller JJ, Santos-Cavaiola T. Initiation and titration of basal insulin in primary care: barriers and practical solutions. J Am Board Fam Med. 2019;32:431-447.
Peyrot M, Barnett A, Meneghini L, Schumm-Draeger P. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabetic Med. 2012;29(5):682-689.
Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. 2018;20(3):488-496.
Okemah J, Peng J, Quiñones M. Addressing clinical inertia in type 2 diabetes mellitus: a review. Adv Ther. 2018;35(11):1735-1745.
Polinski JM, Smith BF, Curtis BH, Seeger JD, Choudhry NK, Connolly JG. Barriers to insulin progression among patients with type 2 diabetes: a systematic review. Diabetes Educ. 2013;39(1):53-65.
United Kingdom diabetes report 2000-2045 [Internet]. Available from: https://diabetesatlas.org/data/en/country/209/gb.html. [cited 2023 Sep 21].
Xu G, Liu B, Sun Y, et al. Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based study. BMJ. 2018;362:1497.
Khunti K, Gomes MB, Pocock S, Shestakova MV, Pintat S, Fenici P. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab. 2018;20(2):427-437.
Seidu S, Than T, Kar D, Lamba A, Brown P, Zafar A. Therapeutic inertia amongst general practitioners with interest in diabetes. Prim Care Diabetes. 2018;12(1):87-91.
Khunti K, Ceriello A, Cos X, Block C. Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2018;137:137-148.
Khunti K, Nikolajsen A, Thorsted B, Andersen M, Davies MJ, Paul S. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016;18(4):401-409.
Clinical Practice Research Datalink | CPRD [Internet]. Available from: https://cprd.com/ [cited 2023 Apr 11]
Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20-29. Available from: https://pubmed.ncbi.nlm.nih.gov/22762315/
Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the Diabetes & Aging Study). Diabetes Care. 2019;42(3):416-426.
Anderson JE. Combining glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors to target multiple organ defects in type 2 diabetes. Diabetes Spectrum. 2020;33(2):165-174.
Ghouse J, Isaksen JL, Skov MW, Lind B, Svendsen JH, Kanters JK. Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes. Diabetes Obes Metab. 2020;22(2):231-242.
Bruce DG, Davis WA, Davis TM. Glycaemic control and mortality in older people with type 2 diabetes: the Fremantle diabetes study phase II. Diabetes Obes Metab. 2018;20(12):2852-2859.
Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
Reaven PD, Moritz TE, Schwenke DC, Anderson RJ, Criqui M, Detrano R. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes. 2009;58(11):2642-2648.
Gimeno-Orna JA, Castro-Alonso FJ, Boned-Juliani B, Lou-Arnal LM. Fasting plasma glucose variability as a risk factor of retinopathy in type 2 diabetic patients. J Diabetes Complications. 2003;17(2):78-81.
Jun JE, Lee S, Lee Y, Ahn JY, Kim G, Jin S. Glycated albumin and its variability as an indicator of cardiovascular autonomic neuropathy development in type 2 diabetic patients. Cardiovasc Diabetol. 2017;16(1):1-9.
Bouchi R, Babazono T, Mugishima M, Yoshida N, Nyumura I, Toya K. Fluctuations in HbA1c are associated with a higher incidence of cardiovascular disease in Japanese patients with type 2 diabetes. J Diabetes Investig. 2012;3(2):148-155.
Hirakawa Y, Arima H, Zoungas S, Ninomiya T, Cooper M, Hamet P. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014;37(8):2359-2365.
Luk AO, Ma RC, Lau ES, Yang X, Lau WW, Yu LW. Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong diabetes registry. Diabetes Metab Res. 2013;29(5):384-390.